[go: up one dir, main page]

WO2010023512A8 - Nouveaux modulateurs de récepteur vanilloïde, procédé pour leur préparation et compositions pharmaceutiques contenant ceux-ci - Google Patents

Nouveaux modulateurs de récepteur vanilloïde, procédé pour leur préparation et compositions pharmaceutiques contenant ceux-ci Download PDF

Info

Publication number
WO2010023512A8
WO2010023512A8 PCT/IB2009/000097 IB2009000097W WO2010023512A8 WO 2010023512 A8 WO2010023512 A8 WO 2010023512A8 IB 2009000097 W IB2009000097 W IB 2009000097W WO 2010023512 A8 WO2010023512 A8 WO 2010023512A8
Authority
WO
WIPO (PCT)
Prior art keywords
pain
vanilloid receptor
receptor modulators
preparation
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2009/000097
Other languages
English (en)
Other versions
WO2010023512A1 (fr
Inventor
Balasubramanian Gopalan
Pal Manojit
Kodimuthali Arumugam
Dhingra Nidhi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Laboratories Ltd
Original Assignee
Matrix Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Laboratories Ltd filed Critical Matrix Laboratories Ltd
Publication of WO2010023512A1 publication Critical patent/WO2010023512A1/fr
Publication of WO2010023512A8 publication Critical patent/WO2010023512A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux modulateurs de récepteur vanilloïde de formule générale I, un procédé pour leur préparation et des compositions pharmaceutiques contenant ceux-ci. Ces nouveaux modulateurs de récepteur vanilloïde sont des agents utiles pour prévenir, améliorer ou traiter des maladies véhiculées par le récepteur vanilloïde et sont utiles, par exemple, pour le traitement de la douleur aiguë, la douleur chronique, la douleur nociceptive, la douleur neuropathique, la douleur postopératoire, la douleur dentaire, la douleur cancéreuse, ou la douleur due à la rétinopathie, un accident cérébrovasculaire, l'incontinence urinaire, une affection abdominale inflammatoire, une irritation de la peau, une dermite et des spasmes musculaires. (I) Formule générale (I)
PCT/IB2009/000097 2008-08-28 2009-01-15 Nouveaux modulateurs de récepteur vanilloïde, procédé pour leur préparation et compositions pharmaceutiques contenant ceux-ci Ceased WO2010023512A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2091/CHE/2008 2008-08-28
IN2091CH2008 2008-08-28

Publications (2)

Publication Number Publication Date
WO2010023512A1 WO2010023512A1 (fr) 2010-03-04
WO2010023512A8 true WO2010023512A8 (fr) 2010-08-05

Family

ID=40457335

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/000097 Ceased WO2010023512A1 (fr) 2008-08-28 2009-01-15 Nouveaux modulateurs de récepteur vanilloïde, procédé pour leur préparation et compositions pharmaceutiques contenant ceux-ci

Country Status (1)

Country Link
WO (1) WO2010023512A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104569222A (zh) * 2015-01-29 2015-04-29 深圳爱湾医学技术服务有限公司 一种尿液的处理方法
WO2019140188A1 (fr) 2018-01-11 2019-07-18 Centaurus Therapeutics Inhibiteurs de la dihydrocéramide désaturase pour le traitement d'une maladie
US20200261456A1 (en) 2019-02-15 2020-08-20 Novartis Ag Methods for treating ocular surface pain
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065484A2 (fr) * 2004-11-24 2006-06-22 Abbott Laboratories Composes de chromanyluree inhibant le recepteur du sous-type 1 du recepteur de vanilloide et leurs utilisations
CA2600833A1 (fr) * 2005-03-30 2006-10-05 Merck & Co., Inc. Composes antagonistes du recepteur du glucagon, compositions renfermant de tels composes et methodes d'utilisation
AP2008004432A0 (en) * 2005-10-07 2008-04-30 Glenmark Pharmaceuticals Sa Substituted benzofused derivatives and their use as vanilloid receptor ligands
WO2008059339A2 (fr) * 2006-11-13 2008-05-22 Glenmark Pharmaceuticals S.A. Dérivés d'isoquinoline comme modulateurs des récepteurs vanilloïdes
CN101563318A (zh) * 2006-12-20 2009-10-21 艾博特公司 作为trpv1香草素受体拮抗剂用于治疗疼痛的n-(5,6,7,8-四氢萘-1-基)脲衍生物以及相关化合物

Also Published As

Publication number Publication date
WO2010023512A1 (fr) 2010-03-04

Similar Documents

Publication Publication Date Title
WO2011044506A3 (fr) Composés sulfonés et leurs procédés de fabrication et d'utilisation
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
PH12012500646A1 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
WO2008152099A3 (fr) Aryl/hétarylamides en tant que modulateurs du récepteur ep2
EA200802020A1 (ru) Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
WO2009069032A3 (fr) Nouveaux agonistes des récepteurs des glucocorticoïdes
CL2009000135A1 (es) Compuestos derivados de 1,4-benzodiazepinas sustituidas, inhibidores de dipeptidilpeptidasa iv (dpp-iv); composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de enfermedades tales como diabetes tipo 2, cataratas, glaucoma, hipertrofia prostatica benigna, cancer, entre otras; compuestos intermediarios.
WO2010093727A8 (fr) Quinazolinones en tant qu'inhibiteurs de prolyle hydroxylase
MX2020004099A (es) Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
WO2010057112A3 (fr) Variants génétiques intervenant dans la cognition humaine et leurs procédés d'utilisation comme cibles diagnostiques et thérapeutiques
EA201200002A1 (ru) Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
WO2010071826A3 (fr) Procédés de traitement d'une maladie liée aux ostéoclastes, composés et compositions pour ceux-ci
CL2007002272A1 (es) Compuestos derivados de n-metil-c-normorfinano; composicion farmaceutica; y uso para la reduccion de efectos secundarios del tratamiento de opioides tales como constipacion y nauseas, y para tratar trastornos mediados por la actividad de receptores o
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
WO2008097924A3 (fr) Compositions pharmaceutiques comprenant des analogues du dextrométhorphane pour le traitement de troubles neurologiques
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MX2012002481A (es) Compuestos terapeuticos de aril-amido-arilo y su uso.
TW200611695A (en) Pyrrolopyridine derivatives
WO2010129048A3 (fr) Composés thérapeutiques
WO2010094734A3 (fr) Procédés d'identification de composés utiles pour le diagnostic et le traitement de maladies liées à une inflammation
EP4357334A3 (fr) Composés oligonucléotidiques conjugués, leurs procédés de fabrication et leurs utilisations
WO2010023512A8 (fr) Nouveaux modulateurs de récepteur vanilloïde, procédé pour leur préparation et compositions pharmaceutiques contenant ceux-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09785786

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09785786

Country of ref document: EP

Kind code of ref document: A1